Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 9,026 shares, an increase of 319.0% from the June 30th total of 2,154 shares. Based on an average trading volume of 90,174 shares, the days-to-cover ratio is presently 0.1 days.
Ono Pharmaceutical Price Performance
Shares of OPHLY opened at $4.94 on Tuesday. The firm has a 50-day moving average of $4.84 and a 200-day moving average of $5.01. Ono Pharmaceutical has a one year low of $3.55 and a one year high of $5.75.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
See Also
- Five stocks we like better than Ono Pharmaceutical
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
